Trials / Completed
CompletedNCT01450449
Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme
A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- International Atomic Energy Agency · Other Government
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two treatment groups in a 1:1 ratio and will be stratified by age, Karnofsky Performance Status and extent of the surgical resection. This study will assess the effect of a one-week radiotherapy regimen in comparison with a three-week radiotherapy regimen on the survival of elderly and/or frail patients with glioblastoma multiforme (Frail: ≥\>50 years old and with a KPS of 50% or less50%-70%; Elderly and frail: ≥65 years and with a KPS of 50% - 70%; Elderly: ≥65 years and with a KPS of 80% - 100%).
Detailed description
This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two treatment groups in a 1:1 ratio and will be stratified by: * Age (\<65 and ≥65 years old) * Karnofsky Performance Status (≤70 and \> 7050 or higher) * Extent of the resection at surgery (biopsy only versus complete/near total and gross total or incomplete /partial resection) Randomization: Patients will be randomized to receive one of the two following treatments: Arm 1: * Short Radiotherapy * 25 Gy/5 fractions * 1 week (5 fractions per week) Arm 2: * Regular Radiotherapy * 40 Gy/15 fractions * 3 weeks (5 fractions per week)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiotherapy | 25 Gy in 5 daily fractions over 1 week |
| RADIATION | Radiotherapy | 40 Gy in 15 daily fractions over 3 weeks |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2013-12-01
- Completion
- 2014-11-01
- First posted
- 2011-10-12
- Last updated
- 2015-03-24
Locations
15 sites across 14 countries: Argentina, Belarus, Brazil, Canada, Chile, Estonia, Georgia, India, Indonesia, Ireland, Poland, Thailand, Tunisia, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01450449. Inclusion in this directory is not an endorsement.